Non-Small Cell Lung Cancer Market:
WiseGuyReports.com adds “Non-Small Cell Lung Cancer – Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018” reports to its database.
Non-Small Cell Lung Cancer (NSCLC) is any epithelial lung cancer, except small cell lung carcinoma. NSCLC contributes around 85% of the total lung cancer. The chemotherapy for NSCLC is comparatively intense as compared to small cell lung carcinoma. Most of the NSCLC affected patients treated by surgical means through chemotherapy extensively used pre-operatively and post-operatively.
The chances of survival are comparatively less than small cell lung carcinoma. People who undergo treatment from the early stage have a high probability (70% ) of survival for the next five years. The overall number is not impressive, though. The overall rate of survival for at least five years is only 14%. The chances of survival decreased from stage one to stage four in a significant manner. For stage one, the survival rate is 47%, stage two is around 30%, stage three is about 10%, the number reaches 1% during the final stage.
Most of the NSCLC detected during the third phase; as a result, the demand for phase three drugs is continuously increasing. The forecast suggests that the market for phase three drugs will show an impressive compound annual growth rate shortly.
Market Segmentation of Non-Small Cell Lung Cancer Market
The global market of Non-Small Cell Lung Cancer drugs can be segmented into Types of Treatment, End User, and Region.
Based on Types of Treatment, the market can further be classified into Radiation Therapy, Chemotherapy, Surgery, and Immunotherapy.
Among them, chemotherapy tops the chart in terms of market share due to its usage before and after the surgery.
The Surgery segment is anticipated to show significant growth in the coming future, as surgery becomes necessary for stage three patients.
The End User segment further divided into Clinical trials, Hospitals, Research Centers, and Others.
Geographical Segmentation of Non-Small Cell Lung Cancer Market
The geographical segmentation of Non-Small Cell Lung Cancer drugs (for stage three) includes a wide range of countries and regions. Some of the crucial areas are Europe, Russia, Italy, Germany, the UK, Spain, France, Asia Pacific, India, Japan, China, ASIAN countries, North America, Canada, Mexico, the USA, South America, Argentina, Brazil, the Middle East and African region, Saudi Arabia and South Africa.
The North American region is leading the industry in terms of market share. Investment in the research and development sector and usage of advanced technology are the primary reason behind the region’s success. The europian market is performing well, owing to the sizeable infrastructural advantage.
Recent Happenings from the Industry
Though chemotherapy extensively used for NSCLC, the results were not as expected. Recently, a major firm published data for a new first-line treatment. The treatment includes a combination of a couple of immunotherapy drugs. The drug combination will improve the survival rate as compared to chemotherapy. The new drug will be a combination of low-dose ipilimumab and nivolumab. The combo can potentially offer a first-line of defense. The increasing research will improve the price of medicine and can be accessible by everyone.
For further information on this report, visit – https://www.wiseguyreports.com/reports/2867778-non-small-cell-lung-cancer-global-api-manufacturers-marketed-and
Ph: +1-646-845-9349 (US); +44 208 133 9349 (UK)